Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-22 pathway (IL-22 pathway (IL-22))
- Target
- IL-22 pathway (IL-22)
- Molecular classification
- Cytokine signaling pathway
01
Overview
The interleukin 22 pathway encompasses cellular events triggered by binding of interleukin-22—a member of the interleukin-10 family—to its heterodimeric cell surface receptor composed of interleukin-10 receptor subunit beta (IL-10R2) and interleukin-22 receptor subunit alpha (IL-22R1). This interaction activates intracellular kinases such as JAK1/Tyk2 leading predominantly to STAT3 phosphorylation but also involving MAPK pathways. The biological outcome includes enhanced epithelial barrier function through increased cell survival/proliferation and antimicrobial peptide secretion, with important roles at mucosal surfaces during infection/inflammation. Dysregulation contributes both to protection from tissue damage/infection as well as pathogenesis in autoimmune disease/cancer depending on context.
- Other names
- IL-22Interleukin 22T-cell-derived inducible factorIL-D110IL-TIFTIFazcyto18
02
Mechanism of action
Potential mechanisms include: Neutralization of circulating/interstitial interleukins using monoclonal antibodies. Blockade of cytokine-receptor interactions. Inhibition of downstream JAK/STAT signal transduction pathways.
03
Biological functions
Immune response modulationEpithelial cell survival and proliferationTissue repair and regenerationAntimicrobial peptide production
04
Disease associations
Inflammatory diseases (e.g., rheumatoid arthritis, psoriasis)Autoimmune diseases (e.g., systemic lupus erythematosus)Infectious diseases including viral infections like COVID-19Cancer development/progression in some contextsCardiovascular disease including myocardial injury/ischemia-reperfusion injury
05
Safety considerations
Balancing tissue-protective versus pro-inflammatory effects; excessive activation can contribute to chronic inflammation or cancer risk while inhibition may impair mucosal defense/healing capacity.Potential for off-target immune suppression leading to infection risk when blocking upstream regulators like JAKs or broad-spectrum immunomodulators.
06
Interacting drugs
Experimental biologics modulating recombinant human IL-22
2 more in the full profile.
07
Biomarkers
Circulating levels of interleukin-17A and interleukin-23 alongside interleukin-6.Expression levels/phosphorylation status of STAT3 in affected tissues.
Beyond the preview
Go deeper on Interleukin-22 pathway (IL-22 pathway (IL-22)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interleukin-22 pathway (IL-22 pathway (IL-22)).